Clinical trial
An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
NCT01615029 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- June 26, 2012
- Completion date
- October 23, 2024
- Enrollment
- 45 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.